THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook (ISSN 2644-2787 | Digital ISSN 2644-2787) is an industry magazine focused on the U.S. pharmaceutical and life sciences technology landscape, helping organizations navigate a sector defined by regulatory complexity, scientific advancement, and evolving patient expectations. Founded in 2014, the magazine reaches over 121,000 qualified subscribers across the U.S.
At its core, Pharma Tech Outlook operates as a peer-driven platform where industry leaders and decision-makers share real-world insights, challenges, and strategies. The publication emphasizes practical, experience-led perspectives, offering a grounded view of how pharmaceutical organizations are adopting technology to improve development, manufacturing, and compliance outcomes.
OUR Mission
Pharma Tech Outlook aims to empower organizations and industry leaders to make informed decisions on the technologies, strategies, and solutions shaping the future of pharmaceutical innovation. As a knowledge-sharing platform, it bridges the gap between pharmaceutical companies, technology providers, and stakeholders working to enhance efficiency, ensure compliance, and improve patient outcomes.
Editorial Focus and Coverage
Pharma Tech Outlook features perspectives from pharmaceutical executives, researchers, and technology leaders on how organizations evaluate, adopt, and scale solutions across the pharma ecosystem. The publication covers key areas such as drug design and development, manufacturing processes, drug delivery systems, regulatory compliance, infrastructure, and emerging pharmaceutical technologies.
Alongside leadership insights, the magazine highlights organizations delivering impactful solutions across pharmaceutical technologies, tools, and services. Companies are identified through a structured methodology, involving nominations from the publication’s subscriber network across the U.S., combined with editorial research and insights from an industry advisory panel, ensuring a credible and balanced view of the evolving pharmaceutical landscape.
As the industry adapts to new models of data-driven decision-making, personalized medicine, and regulatory oversight, Pharma Tech Outlook captures how organizations are transforming innovation into scalable and compliant solutions.
With editorial offices in Fremont, CA; Fort Lauderdale, FL; London, UK; and Singapore, Pharma Tech Outlook brings a global perspective to the developments shaping the pharmaceutical technology ecosystem.

100+ CXOs and senior leaders from public enterprises

600+ CXOs and senior leaders from private companies

Industry leaders responsible for research, development, manufacturing, regulatory compliance, and pharmaceutical innovation
These contributors include executives, researchers, and industry specialists who bring firsthand experience and practical insight into the evolving pharmaceutical landscape. Their perspectives reflect individual expertise and are intended to inform broader industry conversations.
Pharma Tech Outlook maintains a contributor-driven, insight-focused editorial policy. The publication emphasizes accuracy, clarity, and practical relevance for decision-makers, while presenting a balanced mix of expert commentary and curated industry perspectives. This ensures readers can engage with the content confidently and understand its context within the broader pharmaceutical ecosystem.

“Akadeum Life Sciences was thrilled to be featured in Pharma Tech Outlook, and we’ve been incredibly impressed with the reprints that we’ve received. They’ve been a valuable asset for our sales team, and we’re already seeing an increase in interest from potential clients as a result. We would highly recommend Pharma Tech Outlook to any business looking to gain exposure and establish themselves as a leader in their industry.”
Ken Gordon, VP, Commercial
“De Dietrich Process Systems was thrilled to be featured in Pharma Tech Outlook, and we’ve been incredibly impressed with the reprints that we’ve received. We would highly recommend Pharma Tech Outlook to any business looking to gain exposure and establish themselves as a leader in their industry”
Jennifer Mayo, Marketing Specialist
“Recognition by Pharma Tech Outlook is a testament to our company’s dedication to innovating state-of-the-art drug delivery technologies. We are proud to be among Pharma Tech Outlook’s featured companies and recognize the publication for their commitment to showcasing truly next-generation solutions at the forefront of the industry”
MICHAEL HLAVSA, Chief Financial Officer
“Cadrenal Therapeutics is deeply appreciative of Pharma Tech Outlook for their outstanding feature on our company in the latest issue. The reprints have played a pivotal role in elevating our company’s profile and bolstering our reputation within the industry. Kudos to your entire team for their exceptional work”
Quang X. Pham, Chairman and CEOHaichen Yang, MD, MA, MBA, Vice President, Clinical Research
Historical Control in Gene Therapy Clinical DevelopmentLina Parra Cartagena, Associate Director of Finance
The Impact of AI on FP&A in the Life Sciences SectorVictoria Sanjurjo, Medical Director, Clinical Development
Bridging the Diversity DivideDottie Barr, Senior Vice President Manufacturing & Technical Operations
Innovation and Excellence in Radiopharmaceutical OperationsSherene Min, VP, Head of Clinical Development
Children are not just small adults: The challenges of developing new medicines for Children Living with HIVMaribelle Guloy, Director of Clinical Development
Charting a Trailblazing Path in Clinical DevelopmentLone Baekgaard, Vice President of Animal and Plant Biosolutions R&D
Biosolutions R&D: Driving Meaningful Impact in the Agricultural Value ChainDialysis Drug Development Where Continuity and Clinical Fit Matter
Ensuring Regulatory Excellence with Pharma Compliance Solutions